KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that clinical data on its investigative new drug PV-10 for the treatment of melanoma will be presented at the 2014 Beijing International Melanoma Congress. The presentation, by Dr. Sanjiv Agarwala of the St. Luke’s Cancer Center, is titled, “Current Perspectives on Intralesional Therapies.” It is scheduled for 5:30 pm local time, on Saturday, October 18, 2014.
Dr. Agarwala said, “I am very pleased to be presenting our data at the Beijing International Melanoma Congress. I am grateful to the organizers, Peking University Cancer Hospital and the Chinese Society of Clinical Oncology, for their invitation to address one of the most important assemblies of melanoma experts in the world.”
Help employers find you! Check out all the jobs and post your resume.
